Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Ascendis Pharma (ASND – Research Report) today and set a price target of ...

JPMorgan analyst Jessica Fye adjusted the price target for Ascendis Pharma (NASDAQ:ASND), a $7.74 billion biotech company, to $167.00, a slight increase from the previous $165.00, while reiterating ...

Ascendis Pharma boasts several commercial stage products. Read why ASND stock is an interesting speculative investment ...

We recently published a list of 12 High Growth International Stocks to Invest in Now. In this article, we are going to take a ...

Chicago Partners Investment Group LLC decreased its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND – Free Report) by 14.0% in the fourth quarter, HoldingsChannel reports. The firm owned 5,225 ...

Ascendis Pharma A/S has a 52 week low of $111.09 and a 52 week high of $161.00. The stock’s fifty day moving average is $133.63 and its 200-day moving average is $132.89. About Ascendis Pharma A/S ...

Tazeen Ahmad, an analyst from Bank of America Securities, maintained the Buy rating on Ascendis Pharma (ASND – Research Report). The associated ...

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD).

COPENHAGEN, Denmark, Jan. 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided a business and strategic roadmap update, including planned 2025 key corporate milestones.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Ascendis Pharma A/S (Nasdaq: ASND) today provided a business and strategic roadmap update, including planned 2025 key corporate milestones. Ascendis President and CEO Jan Mikkelsen will present ...